Anthropic's Push Into AI Drug Discovery and Medical Research

AI has the potential to rapidly accelerate the pace of drug discovery and the development of healthcare interventions.

With the release of Claude Science, this potential could soon evolve into practical reality for all Claude paid subscribers.

Anthropic’s “AI workbench for scientists” aims to support medical researchers by providing open access to an AI agent equipped with more than 60 curated skills and connectors spanning a range of life science disciplines, all within an interface designed for the unique demands of scientific research. 

Anthropic will also leverage its new product to pursue its own research and drug development programmes for rare and neglected diseases.

“We’re doing this because we believe first and foremost that to build the right models, products and tools to accelerate the industry, we need to live it along with all of you,” says Eric Kauderer-Abrams, Head of Life Sciences at Anthropic.

“We believe in the power of tight feedback loops, and there’s no substitute for having our own experiences alongside you all in the trenches trying to develop drugs.” 

Anthropic’s healthcare history

Although the launch of Claude Science marks a significant milestone in Anthropic’s healthcare capabilities, it is not the company’s first incursion into the space.

In October 2025, Anthropic released Claude for Life Sciences, a suite of plug-ins and connectors linked to scientific research platforms that enabled the standard Claude LLM to better support medical researchers, clinical coordinators and regulatory affairs managers.

In an interview discussing the release of Claude for Life Sciences, Eric explains, “When we talk about the beneficial use cases of AI and all the amazing things that we can do in the world with the frontier AI that we're developing…the number one place that we at Anthropic are excited about applying it is within biology and the life sciences.”

Claude Science is significant as it is a standalone offering, placing it in the same bracket as the widely used Claude Code and Claude Cowork products – a clear signal that AI’s healthcare uses will be a core focus for Anthropic moving forward.

Anthropic has also begun building its own specialised wet labs and strategically acquiring companies operating in the biotech space to bring practical expertise on running scientific programmes in-house.

Research use cases

Early adopters are already using Claude Science to speed up complex medical research across areas, such as single-cell RNA sequencing, CRISPR screen design, protein structure prediction and cheminformatics. 

These test users say the platform has helped identify promising drug targets, automate literature reviews that once took years to complete and cut genomic analysis times.

Major healthcare companies use Claude for a range of tasks, highlighting the potential for Anthropic’s dedicated life sciences product to accelerate healthcare discoveries and operational efficiencies as adoption spreads.

"Claude, paired with internal knowledge libraries, is integral to Sanofi's AI transformation,” says Emmanuel Frenehard, Chief Digital Officer at Sanofi.

“We're seeing efficiency gains across the value-chain, while our enterprise deployment has enhanced how teams work. 

“This collaboration with Anthropic augments human expertise to deliver life-changing medicines faster to patients worldwide." 

Louise Lind Skov, Director of Content Digitalisation at Novo Nordisk, explains: "We've consistently been one of the first movers when it comes to document and content automation in pharma development. 

“Our work with Anthropic and Claude has set a new standard – we're not just automating tasks, we're transforming how medicines get from discovery to the patients who need them."

A sharpening focus for big tech

There is a rapidly growing number of AI-powered scientific discovery platforms aimed at helping researchers design experiments, analyse biological data, review literature and accelerate drug discovery.

Microsoft Discovery, Google DeepMind and NVIDIA’s BioNeMo are just a few examples of tech’s biggest companies harnessing the power of AI to compress R&D timelines and streamline scientific operations.

However, Claude Science appears to be among the first dedicated life sciences products released by a general-purpose frontier AI company open for public use.